CliffBio
small molecule

ZYDELIG

IDELALISIB

Loss of exclusivitySeptember 2033latest FDA-listed patent expiry
CompanyGilead Sciences →View the full company profile on CliffBio

Drug detail

Brand nameZYDELIG
Active ingredientIDELALISIB
Strength100MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2014
Marketing statusRX

Listed patents

PatentExpiresType
9469643September 2033substance
8865730March 2033substance, product
10730879March 2033substance, product
9492449March 2030use U-1914

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZYDELIG patent cliff — loss of exclusivity September 2033 | CliffBio